Oser Communications Group

Chain Drugstore Daily TSE Aug 26 2014

Issue link: http://osercommunicationsgroup.uberflip.com/i/365686

Contents of this Issue

Navigation

Page 0 of 63

O s e r C o m m u n i c a t i o n s G ro u p Bo s to n Tu e s d a y, Au g u s t 2 6 , 2 0 1 4 AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS The practice of pharmacy is chang- ing. Industry mar- gins from filling prescriptions have been on a steady decline for several years and are continu- ing on the downward trend. Conversely, margins for cognitive pharmacy services are increasing. According to the APhA, more than 90 percent of patients who received wellness coaching in a pharma- cy were satisfied with the service and showed improved outcomes across mul- tiple wellness indicators. Additionally, a study by the National Institute of Health SUCCESSFULLY MANAGE CLINICAL INITIATIVES WITH RXTOUCH An interview with Bill Versosky, V.P. of Sales and Marketing, Anda, Inc. CDD: Tell our readers about your company. What's your main line of business? BV: Anda, Inc., a division of Actavis, is a leading full-line distributor of pharma- ceutical and specialty products to chain and independent pharmacies, alternate care providers, hospitals and physicians' offices nationwide. Established in 1992, Rexam Prescription Products is now Centor The healthcare business formerly known as Rexam Prescription Products, Inc. is chang- ing to Centor, following the company's May 2, 2014 acquisition by Montagu. Centor will continue to operate in its cur- rent structure and locations and customer contacts will remain unchanged. Centor's business remains unaffected by this tran- sition, and customers will not notice any change in the way they do business with Centor moving forward. On July 1, 2014, Actavis completed the acquisition of Forest Laboratories, resulting in the creation of a new breed of pharma- ceutical company offering a balance between powerful generic and brand pharmaceutical franchises. The new Actavis now delivers quality generic, brand, branded generic and OTC prod- ucts to more than 60 commercial markets around the world. In addition to being a global leader in generic pharmaceuticals, the new Actavis is now known for leadership in Established in 2010, TAGI Pharma is a wholly owned subsidiary of Precision Dose, Inc., founded with the purpose of penetrating the retail segment and expanding generic opportunities. The Emergence of TAGI With a robust pipeline and product mix, TAGI Pharma is providing market opportunities in both retail and institu- tional segments. It maintains product emphasis on tablets and capsules while encompassing liquids, powders, Continued on Page 61 An interview with David Biernbaum, Master- Broker and National Business Development for TriCalm Anti-Itch. CDD: What are the basic criteria for any new client or brand that David Biernbaum & Associates LLC takes on for national sales distribution and business develop- ment? DB: Innovation, point of differentiation, shelf-productivity, aggressive advertising Continued on Page 61 Continued on Page 60 ANDA DELIVERS CUSTOMIZED PROGRAMS, EXCEPTIONAL SERVICE ALL THE LATEST NEWS FROM CENTOR QUALITY AND SERVICE FROM TAGI PHARMA ACTAVIS DELIVERS QUALITY MEDICINES TRICALM SEES EXPLOSIVE SALES GROWTH WITH RETAIL CUSTOMERS Continued on Page 60 Continued on Page 60 Continued on Page 47 Open any news- paper and it is not uncommon to find a disturbing arti- cle pertaining to the societal problem of illicit drug use. While controlled sub- stances such as pain relievers clearly serve specific and valid healthcare needs, these products are also prone to abuse. As such, it often becomes very difficult for a healthcare provider to dif- ferentiate between legitimate and illicit use of these products. Industry Sanctions One approach toward addressing the An interview with Walt Kaczmarek, President and GM, Multi-Source, M a l l i n c k r o d t Pharmaceuticals. CDD: Tell our readers about your company. What's your main line of business? WK: Mallinckrodt Pharmaceuticals combines more than 146 years of expertise with the determined focus needed to solve the complex specialty pharmaceutical challenges of today. Continued on Page 61 CONTROLLED SUBSTANCE ABUSE IS A SOCIETAL PROBLEM CORPORATE PROFILE: MALLINCKRODT Continued on Page 57

Articles in this issue

view archives of Oser Communications Group - Chain Drugstore Daily TSE Aug 26 2014